Phenotypic landscape of granulocytes and monocytes by multiparametric flow cytometry: A prospective study of a 1-tube panel strategy for diagnosis and prognosis of patients with MDS.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Wiley-Liss Country of Publication: United States NLM ID: 101235690 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1552-4957 (Electronic) Linking ISSN: 15524949 NLM ISO Abbreviation: Cytometry B Clin Cytom Subsets: MEDLINE
    • Publication Information:
      Original Publication: Hoboken, N.J. : Wiley-Liss, c2002-
    • Subject Terms:
      Prognosis*; Flow Cytometry/*methods ; Myelodysplastic Syndromes/*diagnosis; Adult ; Aged ; Aged, 80 and over ; Female ; Granulocytes/pathology ; Granulocytes/ultrastructure ; Humans ; Leukocyte Count ; Male ; Middle Aged ; Monocytes/pathology ; Monocytes/ultrastructure ; Myelodysplastic Syndromes/diagnostic imaging ; Myelodysplastic Syndromes/pathology ; Prospective Studies
    • Abstract:
      Background: Multiparametric flow cytometry (MFC) was recently reported to be a helpful additional tool in the diagnosis of myelodysplastic syndromes (MDS). However, numerous aberrancies have been reported that makes their evaluation difficult as part of a routine diagnosis.
      Methods: Here, we validated a 1-tube panel for the evaluation of granulocytic and monocytic maturation by MFC and correlated our findings with diagnosis and prognosis of MDS. A total of 251 samples with MDS suspicion were prospectively analyzed and compared to an internal reference database leading to the calculation of the Diff score.
      Results: The associated specificity and sensitivity values of this scoring system were 92.1% and 60.4% in a first learning cohort and 96.7% and 65.2% in a second independent validation cohort. The combination of the Diff score with the concomitantly calculated Ogata score increased the sensitivity to 74.2% and 78.3% in the learning and validation cohorts, respectively. Finally, a normal Diff score in MDS patients was associated with a significant prolonged progression-free survival.
      Conclusions: Taken together, the present data indicate that our strategy is a sensitive and specific MFC tool for the diagnosis of MDS-related cytopenia(s) which could be also useful for predicting evolution of these diseases.
      (© 2019 International Clinical Cytometry Society.)
    • References:
      Alhan, C., Westers, T. M., Cremers, E. M. P., Cali, C., Witte, B. I., Ossenkoppele, G. J., & van de Loosdrecht, A. A. (2014). High flow cytometric scores identify adverse prognostic subgroups within the revised international prognostic scoring system for myelodysplastic syndromes. British Journal of Haematology, 167, 100-109.
      Alhan, C., Westers, T. M., Cremers, E. M. P., Cali, C., Witte, B. I., Ossenkoppele, G. J., & van de Loosdrecht, A. A. (2016). The myelodysplastic syndromes flow cytometric score: A three-parameter prognostic flow cytometric scoring system. Leukemia, 30, 658-665.
      Bardet, V., Wagner-Ballon, O., Guy, J., Morvan, C., Debord, C., Trimoreau, F., … On behalf of the Groupe Francophone des Myelodysplasies (GFM) and the Groupe d'Etude Immunologique des Leucemies (GEIL). (2015). Multicentric study underlining the interest of adding CD5, CD7 and CD56 expression assessment to the flow cytometric Ogata score in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms. Haematologica, 100, 472-478.
      Chu, S. C., Wang, T. F., Li, C. C., Kao, R. H., Li, D. K., Su, Y. C., … Loken, M. R. (2011). Flow cytometric scoring system as a diagnostic and prognostic tool in myelodysplastic syndromes. Leukemia Research, 35, 868-873.
      Della Porta, M. G., Picone, C., Pascutto, C., Malcovati, L., Tamura, H., Handa, H., … Ogata, K. (2012). Multicenter validation of a reproducible flow cytometric score for the diagnosis of low-grade myelodysplastic syndromes: Results of a European LeukemiaNET study. Haematologica, 97, 1209-1217.
      Duetz, C., Westers, T. M., & van de Loosdrecht, A. A. (2019). Clinical implication of multi-parameter flow cytometry in myelodysplastic syndromes. Pathobiology, 86, 14-23.
      Eidenschink Brodersen, L., Menssen, A. J., Wangen, J. R., Stephenson, C. F., de Baca, M. E., Zehentner, B. K., … Loken, M. R. (2015). Assessment of erythroid dysplasia by “difference from normal” in routine clinical flow cytometry workup. Cytometry. Part B, Clinical Cytometry, 88, 125-135.
      Greenberg, P. L., Tuechler, H., Schanz, J., Sanz, G., Garcia-Manero, G., Solé, F., … Haase, D. (2012). Revised international prognostic scoring system for myelodysplastic syndromes. Blood, 120, 2454-2465.
      Holdrinet, R. S., von Egmond, J., Wessels, J. M., & Haanen, C. (1980). A method for quantification of peripheral blood admixture in bone marrow aspirates. Experimental Hematology, 8, 103-107.
      Kahn, J. D., Chamuleau, M. E. D., Westers, T. M., de Ven, P. M. V., van Dreunen, L., van Spronsen, M., … van de Loosdrecht, A. A. (2015). Regulatory T cells and progenitor B cells are independent prognostic predictors in lower risk myelodysplastic syndromes. Haematologica, 100, e220-e222.
      Kern, W., Bacher, U., Haferlach, C., Alpermann, T., Schnittger, S., & Haferlach, T. (2015). Multiparameter flow cytometry provides independent prognostic information in patients with suspected myelodysplastic syndromes: A study on 804 patients. Cytometry. Part B, Clinical Cytometry, 88, 154-164.
      Lacombe, F., Bernal, E., Bloxham, D., Couzens, S., Porta, M. G. D., Johansson, U., … Béné, M. C. (2016). Harmonemia: A universal strategy for flow cytometry immunophenotyping-A European LeukemiaNet WP10 study. Leukemia, 30, 1769-1772.
      Loken, M. R., van de Loosdrecht, A., Ogata, K., Orfao, A., & Wells, D. A. (2008). Flow cytometry in myelodysplastic syndromes: Report from a working conference. Leukemia Research, 32, 5-17.
      Malcovati, L., Hellström-Lindberg, E., Bowen, D., Adès, L., Cermak, J., del Cañizo, C., … Cazzola, M. (2013). Diagnosis and treatment of primary myelodysplastic syndromes in adults: Recommendations from the European LeukemiaNet. Blood, 122, 2943-2964.
      Matarraz, S., López, A., Barrena, S., Fernandez, C., Jensen, E., Flores-Montero, J., … Orfao, A. (2010). Bone marrow cells from myelodysplastic syndromes show altered immunophenotypic profiles that may contribute to the diagnosis and prognostic stratification of the disease: A pilot study on a series of 56 patients. Cytometry. Part B, Clinical Cytometry, 78, 154-168.
      Mathis, S., Chapuis, N., Debord, C., Rouquette, A., Radford-Weiss, I., Park, S., … Bardet, V. (2013). Flow cytometric detection of dyserythropoiesis: A sensitive and powerful diagnostic tool for myelodysplastic syndromes. Leukemia, 27, 1981-1987.
      Ogata, K., Della Porta, M. G., Malcovati, L., Picone, C., Yokose, N., Matsuda, A., … Dan, K. (2009). Diagnostic utility of flow cytometry in low-grade myelodysplastic syndromes: A prospective validation study. Haematologica, 94, 1066-1074.
      Ogata, K., Nakamura, K., Yokose, N., Tamura, H., Tachibana, M., Taniguchi, O., … Yoshida, Y. (2002). Clinical significance of phenotypic features of blasts in patients with myelodysplastic syndrome. Blood, 100, 3887-3896.
      Porwit, A., van de Loosdrecht, A. A., Bettelheim, P., Brodersen, L. E., Burbury, K., Cremers, E., … Béné, M. C. (2014). Revisiting guidelines for integration of flow cytometry results in the WHO classification of myelodysplastic syndromes-Proposal from the International/European LeukemiaNet Working Group for Flow Cytometry in MDS. Leukemia, 28, 1793-1798.
      Solly, F., Rigollet, L., Baseggio, L., Guy, J., Borgeot, J., Guérin, E., … Béné, M. C. (2013). Comparable flow cytometry data can be obtained with two types of instruments, Canto II, and Navios. A GEIL study. Cytometry A, 83, 1066-1072.
      Valent, P., Orazi, A., Steensma, D. P., Ebert, B. L., Haase, D., Malcovati, L., … Bennett, J. M. (2017). Proposed minimal diagnostic criteria for myelodysplastic syndromes (MDS) and potential pre-MDS conditions. Oncotarget, 8, 73483-73500.
      Wells, D. A., Benesch, M., Loken, M. R., Vallejo, C., Myerson, D., Leisenring, W. M., & Deeg, H. J. (2003). Myeloid and monocytic dyspoiesis as determined by flow cytometric scoring in myelodysplastic syndrome correlates with the IPSS and with outcome after hematopoietic stem cell transplantation. Blood, 102, 394-403.
      Westers, T. M., Cremers, E. M. P., Oelschlaegel, U., Johansson, U., Bettelheim, P., Matarraz, S., … van de Loosdrecht, A. A. (2017). Immunophenotypic analysis of erythroid dysplasia in myelodysplastic syndromes. A report from the IMDSFlow working group. Haematologica, 102, 308-319.
      Westers, T. M., Ireland, R., Kern, W., Alhan, C., Balleisen, J. S., Bettelheim, P., … van de Loosdrecht, A. A. (2012). Standardization of flow cytometry in myelodysplastic syndromes: A report from an international consortium and the European LeukemiaNet Working Group. Leukemia, 26, 1730-1741.
    • Contributed Indexing:
      Keywords: MDS; diagnosis; disease progression; maturation pathways; multiparametric flow cytometry
    • Publication Date:
      Date Created: 20190910 Date Completed: 20210609 Latest Revision: 20210609
    • Publication Date:
      20221213
    • Accession Number:
      10.1002/cyto.b.21843
    • Accession Number:
      31498561